A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
A Phase 1 Open-Label, Multicenter Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HBM7020 in Healthy Adult Participants and Adults With Seropositive Autoimmune Disease
This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020. The study will enroll healthy participants at low doses, followed by participants with moderate to severe autoimmune diseases with predominant B-cell involvement. Eligible participants include patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's disease (SjD), and rheumatoid arthritis (RA).
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Otsuka Call Center
- Telefonnummer: 844-687-3522
- E-mail: otsukaprofessionalservices@otsuka-us.com
Studiesteder
-
-
Queensland
-
Brisbane, Queensland, Australien, 4006
- Rekruttering
- Q-Pharm Pty Ltd
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Ledende efterforsker:
- Wong
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria for Healthy Participants (Part 1)
- Participants who are of non-childbearing potential or are using acceptable contraception.
- Body mass index (BMI) and body weight within an acceptable range.
- Good general health based on medical history, physical examination, electrocardiogram (ECG), and laboratory assessments.
Key Disease-Agnostic Inclusion Criteria for Patient Participants (Part 2)
- BMI and body weight within an acceptable range.
- Adequate hematologic, renal, hepatic, immunologic, and lymphocyte parameters.
Key Disease-Specific Inclusion Criteria for Patient Participants (Part 2)
-
Confirmed autoimmune disease with appropriate supporting autoantibody findings.
-
Stable background therapy prior to dosing.
-
Active moderate to severe disease consistent with protocol-defined disease activity criteria for:
- Systemic lupus erythematosus (SLE)
- Systemic sclerosis (SSc)
- Rheumatoid arthritis (RA)
- Sjögren's disease (SjD)
Key Inclusion Criteria for Rescreening Participants (Part 2)
- Meets Part 2 disease-agnostic inclusion criteria.
- Stable background autoimmune therapy prior to dosing.
- Ongoing active moderate to severe disease based on protocol-defined disease-specific criteria.
Key Exclusion Criteria for Parts 1 and 2
- Pregnant or breastfeeding participants.
- Recent vaccination within protocol-defined timelines.
- Clinically significant medical history or abnormal physical examination findings.
- Clinically significant cardiovascular abnormalities, including blood pressure, heart rate, syncope, or ECG findings.
- Prior or recent therapies or conditions that may interfere with study participation or safety evaluations.
- Severe pulmonary, renal, or cardiac disease, or clinically significant pulmonary hypertension.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Part 1 and Part 2a Dose Escalation
Healthy participants and participants with seropositive systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), or Sjögren's disease (SjD) will receive HBM7020 in sequential dose-escalation cohorts during Part 1 and Part 2a, respectively. |
Liquid formulation, administered through intravenous infusion |
|
Eksperimentel: Part 2b
Eligible patients may receive optional retreatment of HBM7020 in Part 2b |
Liquid formulation, administered through intravenous infusion |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Discontinuations Due to Adverse Events Through Week 48
Tidsramme: Up to Week 48
|
Up to Week 48
|
|
Number of Participants With Signs Characteristic of Cytokine Release Syndrome (CRS), Immune Related Reaction (IRR), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Including Immunosuppression-Related Infection
Tidsramme: Up to Week 24
|
Up to Week 24
|
|
Number of Participants With Dose limiting AE Evaluation During Dose Escalation
Tidsramme: Up to Day 15
|
Up to Day 15
|
|
Number of Participants With Clinically Significant Changes in Vital Signs
Tidsramme: Up to Week 24
|
Up to Week 24
|
|
Number of Participants With Clinically Significant Changes in Physical Examination Findings
Tidsramme: Up to Week 24
|
Up to Week 24
|
|
Change From Baseline in Serum High Sensitivity C-Reactive Protein (hsCRP)
Tidsramme: Up to Week 20
|
Up to Week 20
|
|
Change From Baseline in Serum Erythrocyte Sedimentation Rate (ESR)
Tidsramme: Up to Week 20
|
Up to Week 20
|
|
Change From Baseline in Serum Ferritin
Tidsramme: Up to Week 20
|
Up to Week 20
|
|
Change From Baseline in Serum Immunoglobulin G (IgG)
Tidsramme: Up to Week 20
|
Up to Week 20
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Area Under the Concentration-Time Curve From Time Zero to Last Observable Concentration (AUCt) of HBM7020
Tidsramme: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC∞) of HBM7020
Tidsramme: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Maximum Observed Plasma Concentration (Cmax) of HBM7020
Tidsramme: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Time to Maximum Observed Plasma Concentration (tmax) of HBM7020
Tidsramme: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Number of Participants With Anti-Drug Antibodies (ADA) to HBM7020
Tidsramme: Up to Week 24
|
Up to Week 24
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Muskuloskeletale sygdomme
- Mundsygdomme
- Stomatognatiske sygdomme
- Gigt
- Ledsygdomme
- Reumatiske sygdomme
- Bindevævssygdomme
- Sygdomme i immunsystemet
- Øjensygdomme
- Hudsygdomme
- Xerostomi
- Spytkirtelsygdomme
- Syndromer med tørre øjne
- Sygdomme i tåreapparatet
- Hud- og bindevævssygdomme
- Lupus erythematosus, systemisk
- Sjøgrens syndrom
- Autoimmune sygdomme
- Sklerodermi, systemisk
- Gigt, reumatoid
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 365-201-00001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
IPD-delingstidsramme
Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
IPD-delingsadgangskriterier
Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .